高级检索
当前位置: 首页 > 详情页

Does Ceruloplasmin Defend Against Neurodegenerative Diseases?

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai General Hospital of Nanjing Medical University, China, 200080 [2]Department of Neurology Baoshan Branch, Shanghai General Hospital, China, 200940 [3]Department of Neurology, Shanghai Tong-Ren Hospital, Shanghai Jiao-Tong University School of Medicine, China, 200080
出处:
ISSN:

关键词: Ceruloplasmin iron copper oxidative stress free radicals neurodegeneration neurodegenerative diseases

摘要:
Ceruloplasmin (CP) is the major copper transport protein in plasma, mainly produced by the liver. Glycosylphosphatidylinositol-linked CP (GPI-CP) is the predominant form expressed in astrocytes of the brain. A growing body of evidence has demonstrated that CP is an essential protein in the body with multiple functions such as regulating the homeostasis of copper and iron ions, ferroxidase activity, oxidizing organic amines, and preventing the formation of free radicals. In addition, as an acute-phase protein, CP is induced during inflammation and infection. The fact that patients with genetic disorder aceruloplasminemia do not suffer from tissue copper deficiency, but rather from disruptions in iron metabolism shows essential roles of CP in iron metabolism rather than copper. Furthermore, abnormal metabolism of metal ions and oxidative stress are found in other neurodegenerative diseases, such as Wilson's disease, Alzheimer's disease and Parkinson's disease. Brain iron accumulation and decreased activity of CP have been shown to be associated with neurodegeneration. We hypothesize that CP may play a protective role in neurodegenerative diseases. However, whether iron accumulation is a cause or a result of neurodegeneration remains unclear. Further research on molecular mechanisms is required before a consensus can be reached regarding a neuroprotective role for CP in neurodegeneration. This review article summarizes the main physiological functions of CP and the current knowledge of its role in neurodegenerative diseases.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版
大类 | 2 区 医学
小类 | 2 区 药学 3 区 神经科学
最新[2023]版
大类 | 2 区 医学
小类 | 2 区 药学 3 区 神经科学
JCR分区:
出版当年[2017]版:
Q1 PHARMACOLOGY & PHARMACY Q2 NEUROSCIENCES
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q1 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Shanghai General Hospital of Nanjing Medical University, China, 200080 [2]Department of Neurology Baoshan Branch, Shanghai General Hospital, China, 200940
通讯作者:
通讯机构: [1]Shanghai General Hospital of Nanjing Medical University, China, 200080 [3]Department of Neurology, Shanghai Tong-Ren Hospital, Shanghai Jiao-Tong University School of Medicine, China, 200080 [*1]Shanghai General Hospital of Nanjing Medical University, China, 200080
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21166 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)